Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First

An early, informal conversation between a sponsor and the review division about the supportive data could help reduce the number of ‘breakthrough therapy’ designation requests that are ultimately denied, FDA and sponsors said.